This website uses cookies

Read our Privacy policy and Terms of use for more information.

Good morning, HealthTech insiders. A retinal implant maker just raised $400 million to bring artificial vision closer to the U.S. market. Meanwhile, AI drug-design company Boltz secured $110 million, and a 31-hospital health system chose one revenue cycle platform to replace more than a dozen vendors.

Behind these moves is a broader shift in HealthTech investment and adoption. Companies are moving from proving what their technologies can do to demonstrating what they can deliver commercially. For investors, hospitals and pharmaceutical companies, the next test is increasingly about measurable outcomes, sustainable revenue and the economics of scaling innovation.

In today's Signal:

  • Science Corporation raises $400 million to expand its PRIMA retinal implant across Europe and pursue U.S. approval.

  • Boltz secures $110 million as six of the world's 20 largest pharmaceutical companies use its AI models.

  • WVU Medicine selects Waystar to consolidate more than a dozen revenue cycle vendors across 31 hospitals.

  • Plus: LGI acquires QHR Technologies, Aetna targets improved maternal care, and a2z Radiology AI secures another FDA clearance.

In partnership with

Product teams aren’t short on ideas. They’re missing a system.

Jira Product Discovery gives teams one place to capture customer feedback, prioritize ideas with consistent frameworks, and build living roadmaps everyone can align on. And when it’s time to build, those decisions connect directly to delivery in Jira, so everyone can see how the roadmap turns into real work.

LATEST DEVELOPMENTS

MEDTECH
1. Science Corp Raises $400 Million to Bring Its PRIMA Vision Implant Toward the U.S.

Science Corporation raises $400 million to expand its PRIMA retinal implant in Europe and prepare for U.S. market entry. Source: Science Corporation — PRIMA technology

Science Corporation announced a $400 million Series D on November 17, bringing its total funding above $900 million. Backed by investors including Khosla Ventures, Tenet Healthcare and Y Combinator, the company will use the capital to expand European commercialization of PRIMA, its retinal implant for people with advanced dry age-related macular degeneration, and prepare for U.S. market entry.

The details:

  • The technology: PRIMA uses a wireless, 2 mm photovoltaic chip implanted beneath the retina, paired with specialized glasses that project near-infrared light. The CE-marked system aims to restore functional form vision, including the ability to recognize letters and words. Its European commercial launch began in July 2026.

  • The evidence: In the PRIMAvera study, 18 patients assessed at 36 months could read an average of 29 additional letters, compared with 24.5 at 12 months. Fourteen gained at least 15 letters. The longer-term findings remain unpublished in a peer-reviewed journal.

  • The U.S. pathway: Science is pursuing FDA approval through the Humanitarian Device Exemption pathway. CEO Max Hodak expects U.S. availability in the first half of 2027, although that timeline depends on regulatory approval. Bloomberg and TechCrunch have reported a $3.5 billion valuation.

The Signal: Science is demonstrating a commercial route for brain-computer interfaces beyond experimental cortical implants. European authorization provides an initial market, while the U.S. humanitarian pathway could accelerate access but constrain profitable sales volumes. Reimbursement, patient eligibility and the economics of specialist implantation will determine how far PRIMA can scale.

AI DRUG DESIGN
2. Boltz Raises $110 Million as Big Pharma Adopts Its AI Models

Boltz secures $110 million in Series A funding as its molecular AI models gain traction among leading pharmaceutical companies.

AI drug-design company Boltz announced a $110 million Series A led by Bessemer Venture Partners on November 18. Originating from MIT's biomolecular modeling research, the company says six of the world's 20 largest pharmaceutical companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb, now use its models.

The details:

  • Commercial traction: Boltz introduced proprietary small-molecule and protein-design models in June. Since then, molecular-token usage among paying customers has increased 50-fold, according to the company.

  • The team and investors: CEO Gabriele Corso, CTO Jeremy Wohlwend and research head Saro Passaro helped develop the original open-source models at MIT. Existing backers Andreessen Horowitz, Amplify Partners and others participated alongside new investors.

  • The competing model: On November 19, MSD announced an oncology drug-discovery partnership with Isomorphic Labs. The agreement combines upfront payments, milestones and tiered royalties, illustrating an alternative to Boltz's metered model-access business.

The Signal: AI drug discovery is developing two commercial models: software-like access to molecular design tools and partnership agreements tied to drug development outcomes. Pharma is investing in both, but the decisive evidence remains downstream: whether these systems produce better candidates, reduce experimental costs and ultimately accelerate successful development.

HOSPITAL OPERATIONS
3. WVU Medicine Chooses Waystar to Replace More Than a Dozen Revenue Cycle Vendors

WVU Medicine selects Waystar to consolidate more than a dozen revenue cycle vendors across its 31-hospital network. Official sources: Waystar's November 19 announcement

Waystar announced on November 19 that WVU Medicine had selected its AI-powered revenue cycle platform across its health system, replacing more than a dozen existing vendors. The agreement represents Waystar's largest new-client contract by deal size, although financial terms were not disclosed.

The details:

  • The customer: WVU Medicine operates 31 hospitals across four states, employs more than 47,000 people and generates approximately $10 billion in annual operating revenue. The consolidation targets administrative complexity and financial performance.

  • The platform: Waystar AltitudeAI connects financial clearance, clinical integrity, claims management and denial recovery. Waystar reports processing more than 8.5 billion healthcare payment transactions annually.

  • The financial context: Waystar reported third-quarter revenue of $325.6 million, up 21% year over year, with subscription revenue growing 34%. Its 2026 revenue guidance stands at $1.277 billion to $1.287 billion.

The Signal: WVU Medicine is betting that one integrated platform can outperform a fragmented network of specialized vendors. For Waystar, consolidation strengthens customer relationships and switching costs. For hospitals, however, it introduces greater dependency on a single provider. The real test will be measurable improvements in denials, collections and operating costs after deployment.

QUICK HITS

👀 WHAT WE'RE WATCHING NEXT

  • PRIMA's U.S. approval: The FDA's Humanitarian Device Exemption decision, European expansion and peer-reviewed 36-month clinical results will shape its next commercial phase.

  • AI-designed drug candidates: Watch for named discovery programs, validated development candidates and evidence that Boltz's metered usage translates into measurable pharmaceutical R&D gains.

  • WVU Medicine's financial outcomes: Implementation milestones, denial reductions and cash collection improvements will determine whether enterprise-wide revenue cycle consolidation delivers its promised value.

💰 FOLLOW THE MONEY

The deals:

  • $400M, Science Corporation: Series D funding to expand commercialization of its CE-marked retinal implant and advance its U.S. regulatory strategy.

  • $110M, Boltz: Series A led by Bessemer Venture Partners, backed by growing paid usage and adoption of its molecular AI models.

  • Undisclosed, MSD and Isomorphic Labs: Oncology research collaboration structured around upfront payments, development milestones and royalties.

  • Undisclosed, Waystar and WVU Medicine: Waystar's largest new-client agreement by deal size, consolidating more than a dozen revenue cycle vendors.

The pattern: Capital is increasingly flowing toward HealthTech companies with demonstrated adoption and identifiable buyers. Science is funding commercialization, Boltz is monetizing computational usage, and Waystar is consolidating enterprise spending. The next investment test is whether that adoption produces sustainable revenue and measurable outcomes.

📆 UPCOMING HEALTHTECH EVENTS

  • RSNA 2026: November 29–December 3 | Chicago, USA
    A major imaging conference where AI orchestration, clinical integration and diagnostic workflow automation will take center stage.

  • GIANT Health 2026: December 7–8 | London, UK
    A European digital health gathering focused on health innovation, commercialization and healthcare adoption.

  • ViVE 2027: March 14–17 | Nashville, USA
    A key forum for health IT leaders, with revenue cycle modernization, payer interoperability and enterprise AI among the issues to watch.
    hlth.com

🛠️ Trending HealthTech AI Tools

  • Elsevier ClinicalKey AI: Patient-context clinical intelligence. New functionality connects patient records inside EHR workflows with Elsevier's clinical evidence base, providing cited recommendations from approximately 1,000 journals. Elsevier says the platform is already used at more than 1,200 hospital sites.

  • Philips Advanced Image Insights: Connected imaging AI. Announced ahead of RSNA, this cloud-based service integrates advanced visualization and third-party imaging AI into existing PACS workflows. Built on Philips HealthSuite with AWS, it aims to reduce fragmentation between imaging algorithms and radiologist reporting.

  • Greenway Health Novare: AI-native ambulatory operations. Launched November 16, Novare unifies scheduling, clinical documentation, eligibility, coding and prior authorization on one platform. Its AI agents assist clinical and administrative workflows, while clinicians retain review and approval authority.

🛠️ Trending HealthTech AI Startups

  • Adjective Health, Patient-centered clinical communication. Launched November 19 in Toronto, its adj/ctive platform converts consented clinical conversations into understandable patient summaries while generating aggregated, de-identified insights for life sciences partners. Its consent and data-governance model will be central to adoption.

  • Capstan Medical, Robotic transcatheter heart valves. The company announced the first U.S. robot-assisted transcatheter mitral valve replacement using its investigational system, performed November 9 at The Christ Hospital. The procedure represents an early clinical milestone under an FDA-authorized feasibility study.

  • Tom Health, AI-supported primary care engagement. Launched as a Lumeris affiliate, Tom uses AI for patient outreach, medication support, reminders and scheduling, escalating clinical needs to care teams. Operating with organizations across 14 states, it targets more than three million patient onboardings in 2027.

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

1. Restoring Sight as a Business: Science Corp and PRIMA
We examine PRIMA's clinical evidence, commercial prospects, U.S. regulatory limitations and what its European rollout could mean for the emerging brain-computer interface market.

2. Tokens or Royalties: Who Captures AI Drug-Design Value?
A comparison of Boltz, Isomorphic Labs and competing discovery models, including how software usage, intellectual property and clinical outcomes influence value capture.

3. One Vendor for the Revenue Cycle: The WVU Medicine–Waystar Bet
An analysis of enterprise revenue cycle consolidation, platform economics, switching costs and the operational risks of concentrating critical payment infrastructure.

That's it for today!

A retinal implant, molecular AI models and a hospital payments platform may operate in different markets, but all three face the same challenge: converting technological progress into sustainable commercial value.

For investors and health system leaders, the next meaningful signals will come from clinical adoption, pharmaceutical development outcomes and measurable financial performance.

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.

Until tomorrow,
The HealthTech Signal

Reply

Avatar

or to participate